Systemic mastocytosis with associated hematological neoplasm

Systemic mastocytosis with associated hematological neoplasm is a subtype of advanced systemic mastocytosis characterized by the abnormal clonal proliferation and accumulation of neoplastic mast cells in extracutaneous tissues alongside a concurrent, distinct clonal hematologic malignancy Primarily affecting the bone marrow, peripheral blood, spleen, liver, and gastrointestinal tract, the associated malignancy is most commonly of myeloid lineage—such as a myelodysplastic syndrome, myeloprolifera...

Systemic mastocytosis with associated hematological neoplasm is a subtype of advanced systemic mastocytosis characterized by the abnormal clonal proliferation and accumulation of neoplastic mast cells in extracutaneous tissues alongside a concurrent, distinct clonal hematologic malignancy

Systemic mastocytosis with associated hematological neoplasm is a subtype of advanced systemic mastocytosis characterized by the abnormal clonal proliferation and accumulation of neoplastic mast cells in extracutaneous tissues alongside a concurrent, distinct clonal hematologic malignancy

Primarily affecting the bone marrow, peripheral blood, spleen, liver, and gastrointestinal tract, the associated malignancy is most commonly of myeloid lineage—such as a myelodysplastic syndrome, myeloproliferative neoplasm, chronic myelomonocytic leukemia, or acute myeloid leukemia—though lymphoid disorders can rarely occur Pathophysiologically driven by activating somatic mutations, most frequently *KIT* D816V, the condition manifests clinically with cytopenias, organomegaly, mast cell mediato...

Primarily affecting the bone marrow, peripheral blood, spleen, liver, and gastrointestinal tract, the associated malignancy is most commonly of myeloid lineage—such as a myelodysplastic syndrome, myeloproliferative neoplasm, chronic myelomonocytic leukemia, or acute myeloid leukemia—though lymphoid disorders can rarely occur

Pathophysiologically driven by activating somatic mutations, most frequently *KIT* D816V, the condition manifests clinically with cytopenias, organomegaly, mast cell mediator-release symptoms, and secondary organ dysfunction caused by the dual disease processes

Pathophysiologically driven by activating somatic mutations, most frequently *KIT* D816V, the condition manifests clinically with cytopenias, organomegaly, mast cell mediator-release symptoms, and secondary organ dysfunction caused by the dual disease processes